3-(morpholine-4-carbonyl)xanthen-9-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-(morpholine-4-carbonyl)xanthen-9-one
• 化学式: C₁₈H₁₅NO₄
• 分子量: 309.321
• InChiKey: JISVANNPTDGNAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(morpholine-4-carbonyl)xanthen-9-one 、 (3-methoxyphenyl)magnesium bromide 在 水 、 氯化铵 作用下， 以 四氢呋喃 为溶剂， 以57%的产率得到3-(4-morpholincarbonyl)-9-hydroxy-9-(3-methoxyphenyl)-9H-xanthene
  参考文献：
  名称：

  Synthesis and cancer cell cytotoxicity of substituted xanthenes

  摘要：

  A series of substituted xanthenes was synthesized and screened for activity using DU-145, MCF-7, and HeLa cancer cell growth inhibition assays. The most potent compound, 9g ([N, N-diethyl]-9-hydroxy-9( 3-methoxyphenyl)-9H-xanthene-3-carboxamide), was found to inhibit cancer cell growth with IC50 values ranging from 36 to 50 mu M across all three cancer cell lines. Structure-activity relationship (SAR) data is presented that indicates additional gains in potency may be realized through further derivatization of the compounds (e. g., the incorporation of a 7-fluoro substituent to 9g). Results are also presented that suggest the compounds function through a unique mechanism of action as compared to that of related acridine and xanthone anticancer agents (which have been shown to intercalate into DNA and inhibit topoisomerase II activity). A structural comparison of these compounds suggests the differences in function may be due to the structure of the xanthene heterocycle which adopts a nonplanar conformation about the pyran ring. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.01.018
• 作为产物：
  描述：

  2-溴四苯醌 在 copper(l) iodide 吡啶 、 氯化亚砜 、 硫酸 、 铜 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 3-(morpholine-4-carbonyl)xanthen-9-one
  参考文献：
  名称：

  具有拓扑异构酶活性的基于cr啶和d啶酮的抗疱疹药物的合成和评估。

  摘要：

  对于新的非核苷类抗病毒化合物的发现在治疗疱疹病毒感染方面具有重要意义，并且受到越来越多的关注，因为出现了核苷抗性菌株。使用全细胞病毒诱导的细胞致病性分析，我们测试了一系列取代的三芳基杂环化合物，包括a啶酮，x吨酮和a啶。进一步显示出对单纯疱疹-1和/或单纯疱疹2具有活性的化合物对拓扑异构酶活性的抑制作用，以深入了解其作用机理。结果表明，带有取代的羧酰胺和庞大的9-氨基官能团的the啶类似物能够抑制疱疹感染以及抑制超螺旋DNA的拓扑异构酶II松弛。鉴于氨苄青霉素的作用机理（密切相关，研究充分的9-氨基取代a啶），进一步在DNA拓扑异构酶II裂解试验中测试化合物，以确定化合物是否具有毒性。结果表明，在这项研究中合成的a啶通过与氨s碱不同的机制起作用，很可能是通过阻断拓扑异构酶与DNA的结合（类似于阿克拉比星）。这不仅表明治疗疱疹病毒感染的独特作用机制，而且对靶向拓扑异构酶II活性的抗癌药的开发

  DOI：

  10.1016/j.bmc.2006.04.044

文献信息

• Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity
  作者：John R. Goodell、Avni A. Madhok、Hiroshi Hiasa、David M. Ferguson

  DOI：10.1016/j.bmc.2006.04.044

  日期：2006.8

  of topoisomerase activity to gain insight into the mechanism of action. The results indicate that the acridine analogs bearing substituted carboxamides and bulky 9-amino functionalities are able to inhibit herpes infections as well as inhibit topoisomerase II relaxation of supercoiled DNA. Given the mechanism of action of amsacrine (a closely related, well-studied 9-amino substituted acridine), the compounds

  对于新的非核苷类抗病毒化合物的发现在治疗疱疹病毒感染方面具有重要意义，并且受到越来越多的关注，因为出现了核苷抗性菌株。使用全细胞病毒诱导的细胞致病性分析，我们测试了一系列取代的三芳基杂环化合物，包括a啶酮，x吨酮和a啶。进一步显示出对单纯疱疹-1和/或单纯疱疹2具有活性的化合物对拓扑异构酶活性的抑制作用，以深入了解其作用机理。结果表明，带有取代的羧酰胺和庞大的9-氨基官能团的the啶类似物能够抑制疱疹感染以及抑制超螺旋DNA的拓扑异构酶II松弛。鉴于氨苄青霉素的作用机理（密切相关，研究充分的9-氨基取代a啶），进一步在DNA拓扑异构酶II裂解试验中测试化合物，以确定化合物是否具有毒性。结果表明，在这项研究中合成的a啶通过与氨s碱不同的机制起作用，很可能是通过阻断拓扑异构酶与DNA的结合（类似于阿克拉比星）。这不仅表明治疗疱疹病毒感染的独特作用机制，而且对靶向拓扑异构酶II活性的抗癌药的开发
• Synthesis and cancer cell cytotoxicity of substituted xanthenes
  作者：Rajan Giri、John R. Goodell、Chenguo Xing、Adam Benoit、Harneet Kaur、Hiroshi Hiasa、David M. Ferguson

  DOI：10.1016/j.bmc.2010.01.018

  日期：2010.2

  A series of substituted xanthenes was synthesized and screened for activity using DU-145, MCF-7, and HeLa cancer cell growth inhibition assays. The most potent compound, 9g ([N, N-diethyl]-9-hydroxy-9( 3-methoxyphenyl)-9H-xanthene-3-carboxamide), was found to inhibit cancer cell growth with IC50 values ranging from 36 to 50 mu M across all three cancer cell lines. Structure-activity relationship (SAR) data is presented that indicates additional gains in potency may be realized through further derivatization of the compounds (e. g., the incorporation of a 7-fluoro substituent to 9g). Results are also presented that suggest the compounds function through a unique mechanism of action as compared to that of related acridine and xanthone anticancer agents (which have been shown to intercalate into DNA and inhibit topoisomerase II activity). A structural comparison of these compounds suggests the differences in function may be due to the structure of the xanthene heterocycle which adopts a nonplanar conformation about the pyran ring. (C) 2010 Elsevier Ltd. All rights reserved.